(Q43240682)

17 November 2017

title

A phase 2 trial exploring the effects of high-dose (10,000 IU/day) vitamin D(3) in breast cancer patients with bone metastases (English)

1 reference

17 November 2017

0 references

phase II clinical trial

0 references

author

Eitan Amir

1

1 reference

17 November 2017

4

George Dranitsaris

1 reference

17 November 2017

8

Mark Clemons

1 reference

17 November 2017

6

Reinhold Vieth

1 reference

17 November 2017

Christine E Simmons

2

1 reference

17 November 2017

Orit C Freedman

3

1 reference

17 November 2017

David E C Cole

5

1 reference

17 November 2017

Wei S Ooi

7

1 reference

17 November 2017

language of work or name

English

0 references

publication date

1 January 2010

1 reference

17 November 2017

1 reference

17 November 2017

volume

116

1 reference

17 November 2017

issue

2

1 reference

17 November 2017

page(s)

284-291

1 reference

Vitamin D from Skin: Contribution to Vitamin D Status Compared with Oral Vitamin D in Normal and Anticonvulsant-Treated Subjects

17 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24749

Gains in bone mineral density with resolution of vitamin D intoxication

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24749

1,25-Dihydroxyvitamin D3 inhibitory effect on the growth of two human breast cancer cell lines (MCF-7, BT-20)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24749

7 January 2021

Effects of 1,25 dihydroxyvitamin D3 and its analogues on induction of apoptosis in breast cancer cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24749

7 January 2021

Effects of synthetic vitamin D analogues on breast cancer cell proliferation in vivo and in vitro

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24749

7 January 2021

Geographic variation in breast cancer mortality in the United States: a hypothesis involving exposure to solar radiation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24749

7 January 2021

Sunlight and breast cancer incidence in the USSR.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24749

7 January 2021

Serum 25-hydroxyvitamin D levels in early and advanced breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24749

7 January 2021

Prognostic Effects of 25-Hydroxyvitamin D Levels in Early Breast Cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24749

7 January 2021

Intake of vitamin D and risk of breast cancer--a meta-analysis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24749

7 January 2021

Calcium plus vitamin D supplementation and the risk of breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24749

7 January 2021

Clinical practice. Screening for osteoporosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24749

7 January 2021

Musculoskeletal pain in female asylum seekers and hypovitaminosis D3

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24749

7 January 2021

Factors in human vitamin D nutrition and in the production and cure of classical rickets

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24749

7 January 2021

Environmental factors that influence the cutaneous production of vitamin D

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24749

7 January 2021

Ultraviolet irradiation corrects vitamin D deficiency and suppresses secondary hyperparathyroidism in the elderly.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24749

7 January 2021

Risk assessment for vitamin D

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24749

7 January 2021

25-Hydroxyvitamin D levels in patients treated with high-dosage ergo- and cholecalciferol

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24749

7 January 2021

The Functional Assessment of Cancer Therapy scale: development and validation of the general measure

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24749

7 January 2021

Switching breast cancer patients with progressive bone metastases to third-generation bisphosphonates: measuring impact using the Functional Assessment of Cancer Therapy-Bone Pain

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24749

7 January 2021

Long-term variability of markers of bone turnover in postmenopausal women and implications for their clinical use: the OFELY study.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24749

7 January 2021

Transmission of human herpesvirus 8 by blood transfusion

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24749

7 January 2021

Inhibition of angiogenesis by vitamin D3 analogues

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24749

7 January 2021

Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24749

7 January 2021

Vitamin D supplementation and total mortality: a meta-analysis of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24749

7 January 2021

Safety of vitamin D3 in adults with multiple sclerosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24749

7 January 2021

Markers of bone resorption in patients treated with pamidronate

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24749

7 January 2021

Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24749

7 January 2021

Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24749

7 January 2021

A Phase II trial evaluating the palliative benefit of second-line oral ibandronate in breast cancer patients with either a skeletal related event (SRE) or progressive bone metastases (BM) despite standard bisphosphonate (BP) therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24749

7 January 2021

Studies of the oral bioavailability of alendronate.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24749

7 January 2021

Increased prevalence of primary hyperparathyroidism in treated breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24749

7 January 2021

Increased incidence of nephrolithiasis (N) in lifeguards (LG) in Israel

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24749

7 January 2021

Identifiers

DOI

10.1002/CNCR.24749

1 reference

17 November 2017

1 reference